Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by strategic initiatives and strong demand in the peptide market [1][2]. Revenue Forecast - The company expects revenue for the fiscal year 2025 to be between approximately RMB 5.55 billion and RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of approximately RMB 4.422 billion for 2024 [1]. Profit Forecast - The anticipated profit for 2025 is projected to be between approximately RMB 2 billion and RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of around RMB 592 million for 2024 [1]. Adjusted Net Profit Forecast - The adjusted net profit for 2025 is expected to range from approximately RMB 2 billion to RMB 2.3 billion, reflecting an increase of about 16.3% to 33.7% compared to the adjusted net profit of approximately RMB 1.72 billion for 2024 [1]. Factors Driving Revenue Growth - Revenue growth is attributed to the successful implementation of the "follow-on" strategy, the advantages of the integrated contract research, development, and manufacturing organization (CRDMO) platform, timely project delivery, and strong demand from key clients due to advancements in their R&D pipelines and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [2]. Factors Driving Profit Growth - Profit growth is influenced by the aforementioned revenue increase, cost savings and efficiency improvements achieved through optimized operational management, and fair value gains from financial liabilities recognized in 2025, which contrasts with the fair value losses recorded in 2024 [2]. Factors Driving Adjusted Net Profit Growth - The increase in adjusted net profit is primarily due to the revenue growth and the comprehensive impact of cost savings and efficiency improvements from optimized operational management [2].